Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions frequently mention that the trial involved 1,480 CKD patients and did not find veverimer to significantly slow disease progression, with phrases like 'failed to show significant benefits' and 'another trial that dies in the attempt' conveying skepticism or disappointment. The tone of many posts is analytical, reflecting participants' focus on the trial's results and implications, influenced by technical language and references to the study design and patient outcomes, which underscores the community's depth of engagement despite overall neutral sentiment.
Most discussions highlight that the trial did not show significant benefits of veverimer, reflecting a consensus of disappointment or neutrality regarding the drug's efficacy.
The frequent mentions of the trial's outcomes and high-profile conference presentations indicate a high level of curiosity and relevance among the audience.
Several posts analyze the trial's methodology and compare it with previous studies, suggesting some depth of engagement despite skepticism.
While users are interested, they tend to view the findings as somewhat limited in practical impact, with some expressing the view that it might not change current treatment practices significantly.
En enfermedad renal crónica G4A2 y acidosis metabólica con bicarbonato (BIC) 17 meq/L, veverimer normalizó el BIC, pero no evitó pérdida de función renal, ni eventos cardiovasculares Ensayo clínico VALOR-CKD, otro que muere en el intento
@NephJC @elbaonelida VALOR-CKD: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression from @NavTangri #NephJC #Nephpearls #VisualAbstract by @JasmineNephro
VALOR-CKD: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression from @NavTangri #NephJC #Nephpearls #VisualAbstract by @JasmineNephro
.@NavTangri is up next at the #KidneyWk High-Impact Clinical Trials session, presenting results from @TRICIDA’s VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients With #MetabolicAcidosis https://t.co/z7NEjjR5It
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis https://t.co/MGYAhalvGn
LBCT VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients With Metabolic Acidosis Navdeep Tangri, et al @NavTangri #KidneyWk
Prof. Dr. Roman-Ulrich Müller discusses the methodology and key outcomes of the KETO-ADPKD study on ketogenic diet intervention for patients with autosomal dominant polycystic kidney disease. This study highlights…
Dr Nilufar Mohebbi and Dr Navdeep Tangri review phase 3 studies on renal acidosis treatments, focusing on recent research from the PRESERVETransplant and VALOR-CKD trials, highlighting challenges and advancements in…
Open Access UCL Research: VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis discovery.ucl.ac.uk/id/eprint/10...
@berg_peder The meta-analysis doesn’t include 1480 patient trial of ververimer (cuz it’s not bicarb) which showed no benefit. The notable large trial in the m-a (~750 pts) gets better separation in bicarb levels than the Verv. trial - could be the difference. https://t.co/I60h3WqLYm
RT @edgarvlermamd: VALOR-CKD: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression from @N…
RT @edgarvlermamd: VALOR-CKD: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression from @N…
RT @edgarvlermamd: @NephJC @elbaonelida VALOR-CKD: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CK…
RT @edgarvlermamd: VALOR-CKD: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression from @N…
RT @edgarvlermamd: VALOR-CKD: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression from @N…
RT @edgarvlermamd: @NephJC @elbaonelida VALOR-CKD: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CK…
VALOR-CKD: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression from @NavTangri #NephJC #Nephpearls #VisualAbstract by @JasmineNephro
@NephJC @elbaonelida VALOR-CKD: Among patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression from @NavTangri #NephJC #Nephpearls #VisualAbstract by @JasmineNephro
RT @ISRNM_Social: VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression o…
RT @ISRNM_Social: VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression o…
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis https://t.co/MGYAhalvGn
【RCT】eGFR20-40mL/min/1.73m^2かつ代謝性アシドーシス（血清重炭酸塩12-20mEq/L）のあるCKD患者へのVeverimer投与は、プラセボ投与と比較して、CKD進行の複合転帰を改善させなかった。 #ペ読 https://t.co/PwODuAuyBL
RT @JonathanNefro: En enfermedad renal crónica G4A2 y acidosis metabólica con bicarbonato (BIC) 17 meq/L, veverimer normalizó el BIC, pero…
RT @JonathanNefro: En enfermedad renal crónica G4A2 y acidosis metabólica con bicarbonato (BIC) 17 meq/L, veverimer normalizó el BIC, pero…
RT @JonathanNefro: En enfermedad renal crónica G4A2 y acidosis metabólica con bicarbonato (BIC) 17 meq/L, veverimer normalizó el BIC, pero…
RT @JonathanNefro: En enfermedad renal crónica G4A2 y acidosis metabólica con bicarbonato (BIC) 17 meq/L, veverimer normalizó el BIC, pero…
RT @JonathanNefro: En enfermedad renal crónica G4A2 y acidosis metabólica con bicarbonato (BIC) 17 meq/L, veverimer normalizó el BIC, pero…
RT @JonathanNefro: En enfermedad renal crónica G4A2 y acidosis metabólica con bicarbonato (BIC) 17 meq/L, veverimer normalizó el BIC, pero…
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis. 2024 from @JASN_News https://t.co/VIZG7wgMdZ https://t.co/h9EiJGC9oI
RT @JonathanNefro: En enfermedad renal crónica G4A2 y acidosis metabólica con bicarbonato (BIC) 17 meq/L, veverimer normalizó el BIC, pero…
RT @JonathanNefro: En enfermedad renal crónica G4A2 y acidosis metabólica con bicarbonato (BIC) 17 meq/L, veverimer normalizó el BIC, pero…
En enfermedad renal crónica G4A2 y acidosis metabólica con bicarbonato (BIC) 17 meq/L, veverimer normalizó el BIC, pero no evitó pérdida de función renal, ni eventos cardiovasculares Ensayo clínico VALOR-CKD, otro que muere en el intento
Bikarbonata devamGreat article: VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis. https://t.co/KPedqMURy4 #ReadByQxMD
LBCT VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients With Metabolic Acidosis Navdeep Tangri, et al @NavTangri #KidneyWk
LBCT VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients With Metabolic Acidosis Navdeep Tangri, et al @NavTangri #KidneyWk
.@NavTangri is up next at the #KidneyWk High-Impact Clinical Trials session, presenting results from @TRICIDA’s VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients With #MetabolicAcidosis https://t.co/z7NEjjR5It
RT @anaisabelstark: VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression…
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients With Metabolic Acidosis https://t.co/KoKFDwCH5n #NephTwitter #MedTwitter